Wyeth v. Levine, 555 U.S. 555 (2009)
Wyeth v. Levine marked a significant decision by the U.S.
Does federal law preempt a state-law claim that a drug label lacks adequate warnings when the label has been approved by the FDA?
Federal drug labeling laws do not preempt state-law tort claims unless there is a clear intent by Congress to preempt, or a direct conflict between federal and state law that makes it impossible to comply with both regulations.
The U.S. Supreme Court held that federal drug labeling laws do not preempt state-law claims, affirming the state court's award of damages to Levine.
Wyeth v. Levine is instrumental in understanding preemption in the context of pharmaceutical regulation. It reinforced the notion that state tort law can serve as a consumer protection mechanism, supplementing federal regulatory oversight. Its decision reassured that FDA approval does not render manufacturers immune to state-level product liability claims, thereby maintaining state involvement in safeguarding public health.